• 1
    Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1: 723.
  • 2
    Gallinella G, Venturoli S, Gentilomi G, Musiani M, Zerbini M. Extent of sequence variability in a genomic region coding for capsid proteins of B19 parvovirus. Arch Virol 1995; 140: 111925.
  • 3
    Erdman DD, Durigon EL, Wang QY, Anderson LJ. Genetic diversity of human parvovirus B19: sequence analysis of the VP1/VP2 gene from multiple isolates. J Gen Virol 1996; 77: 276774.
  • 4
    Haseyama K, Kudoh T, Yoto Y, Suzuki N, Chiba S. Analysis of genetic diversity in the VP1 unique region gene of human parvovirus B19 using the mismatch detection method and direct nucleotide sequencing. J Med Virol 1998; 56: 2059.
  • 5
    Umene K, Nunoue T. Genetic diversity of human parvovirus B19 determined using a set of restriction endonucleases recognizing four or five base pairs and partial nucleotide sequencing: use of sequence variability in virus classification. J Gen Virol 1991; 72: 19972001.
  • 6
    Umene K, Nunoue T. The genome type of human parvovirus B19 strains isolated in Japan during 1981 differs from types detected in 1986 to 1987: a correlation between genome type and prevalence. J Gen Virol 1990; 71: 9836.
  • 7
    Hemauer A, Von Poblotzki A, Gigler A et al. Sequence variability among different parvovirus B19 isolates. J Gen Virol 1996; 77: 17815.
  • 8
    Gallinella G, Venturoli S, Manaresi E, Musiani M, Zerbini M. B19 virus genome diversity: epidemiological and clinical correlations. J Clin Virol 2003; 28: 113.
  • 9
    Nguyen QT, Wong S, Heegaard ED, Brown KE. Identification and characterization of a second novel human erythrovirus variant, A6. Virology 2002; 301: 37480.
  • 10
    Nguyen QT, Sifer C, Schneider V et al. Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999; 37: 24837.
  • 11
    Nguyen QT, Sifer C, Schneider V, Bernaudin F, Auguste V, Garbarg-Chenon A. Detection of an erythrovirus sequence distinct from B19 in a child with acute anaemia. Lancet 1998; 352: 1524.
  • 12
    Servant A, Laperche S, Lallemand F et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76: 912434.
  • 13
    Hokynar K, Soderlund-Venermo M, Pesonen M et al. A new parvovirus genotype persistent in human skin. Virology 2002; 302: 2248.
  • 14
    Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A 2005; 102: 128916.
  • 15
    Sanabani S, Neto WK, Pereira J, Sabino EC. Sequence variability of human erythroviruses present in bone marrow of Brazilian patients with various parvovirus B19-related hematological symptoms. J Clin Microbiol 2006; 44: 6046.
  • 16
    Takahashi T, Ozawa K, Takahashi K, Asano S, Takaku F. Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood 1990; 75: 60310.
  • 17
    Mortimer PP, Humphries RK, Moore JG, Purcell RH, Young NS. A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature 1983; 302: 4269.
  • 18
    Ozawa K, Kurtzman G, Young N. Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro. Blood 1987; 70: 38491.
  • 19
    Solheim BG, Rollag H, Svennevig JL, Arafa O, Fosse E, Bergerud U. Viral safety of solvent/detergent-treated plasma. Transfusion 2000; 40: 8490.
  • 20
    Schwarz TF, Serke S, Von Brunn A et al. Heat stability of parvovirus B19: kinetics of inactivation. Zentralbl Bakteriol 1992; 277: 21923.
  • 21
    Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262: 1147.
  • 22
    Brown KE, Hibbs JR, Gallinella G et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994; 330: 11926.
  • 23
    Jordan JA, DeLoia JA. Globoside expression within the human placenta. Placenta 1999; 20: 1038.
  • 24
    Cooling LL, Koerner TA, Naides SJ. Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J Infect Dis 1995; 172: 1198205.
  • 25
    Von Dem Borne AE, Bos MJ, Joustra-Maas N et al. A murine monoclonal IgM antibody specific for blood group P antigen (globoside). Br J Haematol 1986; 63: 3546.
  • 26
    Rouger P, Gane P, Salmon C. Tissue distribution of H, Lewis and P antigens as shown by a panel of 18 monoclonal antibodies. Rev Fr Transfus Immunohematol 1987; 30: 699708.
  • 27
    Srivastava A, Bruno E, Briddell R et al. Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood 1990; 76: 19972004.
  • 28
    Weigel-Kelley KA, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol 2001; 75: 41106.
  • 29
    Weigel-Kelley KA, Yoder MC, Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 2003; 102: 392733.
  • 30
    Munakata Y, Saito-Ito T, Kumura-Ishii K et al. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 2005; 106: 344956.
  • 31
    Heegaard ED, Petersen BL, Heilmann CJ, Hornsleth A. Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J Clin Microbiol 2002; 40: 9336.
  • 32
    Anderson LJ, Tsou C, Parker RA et al. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986; 24: 5226.
  • 33
    Kelly HA, Siebert D, Hammond R, Leydon J, Kiely P, Maskill W. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect 2000; 124: 44957.
  • 34
    Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988; 25: 1513.
  • 35
    Tsujimura M, Matsushita K, Shiraki H, Sato H, Okochi K, Maeda Y. Human parvovirus B19 infection in blood donors. Vox Sang 1995; 69: 20612.
  • 36
    Tolfvenstam T, Enbom M, Ghebrekidan H et al. Seroprevalence of viral childhood infections in Eritrea. J Clin Virol 2000; 16: 4954.
  • 37
    Schwarz TF, Gurtler LG, Zoulek G, Deinhardt F, Roggendorf M. Seroprevalence of human parvovirus B19 infection in Sao Tome and Principe, Malawi and Mascarene Islands. Zentralbl Bakteriol 1989; 271: 2316.
  • 38
    Nascimento JP, Buckley MM, Brown KE, Cohen BJ. The prevalence of antibody to human parvovirus B19 in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo 1990; 32: 415.
  • 39
    Thomas I, Di Giambattista M, Gerard C et al. Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins. Vox Sang 2003; 84: 3007.
  • 40
    Yoto Y, Kudoh T, Haseyama K et al. Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol 1995; 91: 10178.
  • 41
    Wakamatsu C, Takakura F, Kojima E et al. Screening of blood donors for human parvovirus B19 and characterization of the results. Vox Sang 1999; 76: 1421.
  • 42
    Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998; 75: 97102.
  • 43
    Berry PJ, Gray ES, Porter HJ, Burton PA. Parvovirus infection of the human fetus and newborn. Semin Diagn Pathol 1992; 9: 412.
  • 44
    Lundqvist A, Tolfvenstam T, Brytting M, Stolt CM, Hedman K, Broliden K. Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders. Scand J Infect Dis 1999; 31: 11922.
  • 45
    Broliden K, Tolfvenstam T, Ohlsson S, Henter JI. Persistent B19 parvovirus infection in pediatric malignancies. Med Pediatr Oncol 1998; 31: 6672.
  • 46
    Anderson MJ, Cohen BJ. Human parvovirus B19 infections in United Kingdom 1984–86. Lancet 1987; 1: 7389.
  • 47
    Heegaard ED, Laub Petersen B. Parvovirus B19 transmitted by bone marrow. Br J Haematol 2000; 111: 65961.
  • 48
    Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 2000; 40: 12036.
  • 49
    PHLS. Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. BMJ 1990; 300: 116670.
  • 50
    Broliden K. Parvovirus B19 infection in pediatric solid-organ and bone marrow transplantation. Pediatr Transplant 2001; 5: 32030.
  • 51
    Egbuna O, Zand MS, Arbini A, Menegus M, Taylor J. A cluster of parvovirus B19 infections in renal transplant recipients: a prospective case series and review of the literature. Am J Transplant 2006; 6: 22531.
  • 52
    Anderson LJ. Role of parvovirus B19 in human disease. Pediatr Infect Dis J 1987; 6: 7118.
  • 53
    Anderson LJ, Gillespie SM, Torok TJ, Hurwitz ES, Tsou CJ, Gary GW. Risk of infection following exposures to human parvovirus B19. Behring Inst Mitt 1990; 85: 603.
  • 54
    Gillespie SM, Cartter ML, Asch S et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990; 263: 20615.
  • 55
    Woolf AD, Campion GV, Chishick A et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149: 11536.
  • 56
    Miyamoto K, Ogami M, Takahashi Y et al. Outbreak of human parvovirus B19 in hospital workers. J Hosp Infect 2000; 45: 23841.
  • 57
    Evans JP, Rossiter MA, Kumaran TO, Marsh GW, Mortimer PP. Human parvovirus aplasia: case due to cross infection in a ward. Br Med J (Clin Res Ed) 1984; 288: 681.
  • 58
    Frickhofen N, Chen ZJ, Young NS, Cohen BJ, Heimpel H, Abkowitz JL. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994; 87: 81824.
  • 59
    Eis-Hubinger AM, Sasowski U, Brackmann HH, Kaiser R, Matz B, Schneweis KE. Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products. Thromb Haemost 1996; 76: 1120.
  • 60
    Williams MD, Cohen BJ, Beddall AC, Pasi KJ, Mortimer PP, Hill FG. Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang 1990; 58: 17781.
  • 61
    Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997; 72: 110.
  • 62
    Santagostino E, Mannucci PM, Gringeri A et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 1997; 37: 51722.
  • 63
    Plentz A, Hahn J, Knoll A, Holler E, Jilg W, Modrow S. Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products. Transfusion 2005; 45: 18115.
  • 64
    Aberham C, Pendl C, Gross P, Zerlauth G, Gessner M. A quantitative, internally controlled real-time PCR assay for the detection of parvovirus B19 DNA. J Virol Methods 2001; 92: 18391.
  • 65
    Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004; 53: 45975.
  • 66
    Groeneveld K, Van Der Noordaa J. Blood products and parvovirus B19. Neth J Med 2003; 61: 1546.
  • 67
    Blumel J, Schmidt I, Willkommen H, Lower J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002; 42: 10118.
  • 68
    Daly P, Corcoran A, Mahon BP, Doyle S. High-sensitivity PCR detection of parvovirus B19 in plasma. J Clin Microbiol 2002; 40: 195862.
  • 69
    Hayakawa F, Imada K, Towatari M, Saito H. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 2002; 118: 11879.
  • 70
    Pattison JR, Jones SE, Hodgson J et al. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1981; 1: 6645.
  • 71
    Anderson MJ, Jones SE, Fisher-Hoch SP et al. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet 1983; 1: 1378.
  • 72
    Potter CG, Potter AC, Hatton CS et al. Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19). J Clin Invest 1987; 79: 148692.
  • 73
    Anderson MJ, Higgins PG, Davis LR et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152: 25765.
  • 74
    Cartter ML, Farley TA, Rosengren S et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis 1991; 163: 2825.
  • 75
    Musiani M, Manaresi E, Gallinella G, Cricca M, Zerbini M. Recurrent erythema in patients with long-term parvovirus B19 infection. Clin Infect Dis 2005; 40: e1179.
  • 76
    Woolf AD. Human parvovirus B19 and arthritis. Behring Inst Mitt 1990; 85: 648.
  • 77
    Reid DM, Reid TM, Brown T, Rennie JA, Eastmond CJ. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet 1985; 1: 4225.
  • 78
    White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA. Human parvovirus arthropathy. Lancet 1985; 1: 41921.
  • 79
    Naides SJ. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am 1998; 24: 375401.
  • 80
    Saal JG, Steidle M, Einsele H, Muller CA, Fritz P, Zacher J. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 1992; 12: 14751.
  • 81
    Zakrzewska K, Azzi A, De Biasi E et al. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J Med Virol 2001; 65: 4027.
  • 82
    Dijkmans BA, Van Elsacker-Niele AM, Salimans MM, Van Albada-Kuipers GA, De Vries E, Weiland HT. Human parvovirus B19 DNA in synovial fluid. Arthritis Rheum 1988; 31: 27981.
  • 83
    Soderlund M, Von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349: 10635.
  • 84
    Speyer I, Breedveld FC, Dijkmans BA. Human parvovirus B19 infection is not followed by inflammatory joint disease during long term follow-up. A retrospective study of 54 patients. Clin Exp Rheumatol 1998; 16: 5768.
  • 85
    Nikkari S, Luukkainen R, Mottonen T et al. Does parvovirus B19 have a role in rheumatoid arthritis? Ann Rheum Dis 1994; 53: 10611.
  • 86
    Kerr JR, Mattey DL, Thomson W, Poulton KV, Ollier WE. Association of symptomatic acute human parvovirus B19 infection with human leukocyte antigen class I and II alleles. J Infect Dis 2002; 186: 44752.
  • 87
    Jawad AS. Persistent arthritis after human parvovirus B19 infection. Lancet 1993; 341: 494.
  • 88
    Klouda PT, Corbin SA, Bradley BA, Cohen BJ, Woolf AD. HLA and acute arthritis following human parvovirus infection. Tissue Antigens 1986; 28: 3189.
  • 89
    Lu J, Zhi N, Wong S, Brown KE. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis 2006; 193: 58290.
  • 90
    Moffatt S, Tanaka N, Tada K et al. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 1996; 70: 848591.
  • 91
    Mitchell LA. Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J Med Virol 2002; 67: 26774.
  • 92
    Lunardi C, Tiso M, Borgato L et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 1998; 28: 93648.
  • 93
    Hsu TC, Tsay GJ. Human parvovirus B19 infection in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40: 1527.
  • 94
    Magro CM, Dawood MR, Crowson AN. The cutaneous manifestations of human parvovirus B19 infection. Hum Pathol 2000; 31: 48897.
  • 95
    Ferguson PJ, Saulsbury FT, Dowell SF, Torok TJ, Erdman DD, Anderson LJ. Prevalence of human parvovirus B19 infection in children with Henoch-Schonlein purpura. Arthritis Rheum 1996; 39: 8801.
  • 96
    Corman LC, Dolson DJ. Polyarteritis nodosa and parvovirus B19 infection. Lancet 1992; 339: 491.
  • 97
    Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999; 42: 12558.
  • 98
    Meyer O. Parvovirus B19 and autoimmune diseases. Joint Bone Spine 2003; 70: 611.
  • 99
    Graeve JA, Elliott SC. Neurologic symptoms, iron deficiency anemia, and parvovirus infection. J Pediatr 1991; 118: 830.
  • 100
    Lortholary O, Eliaszewicz M, Dupont B, Courouce AM. Parvovirus B19 infection during acute Plasmodium falciparum malaria. Eur J Haematol 1992; 49: 219.
  • 101
    Serjeant GR, Topley JM, Mason K et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet 1981; 2: 5957.
  • 102
    Lefrere JJ, Courouce AM, Bertrand Y, Girot R, Soulier JP. Human parvovirus and aplastic crisis in chronic hemolytic anemias: a study of 24 observations. Am J Hematol 1986; 23: 2715.
  • 103
    Harris JW. Parvovirus B19 for the hematologist. Am J Hematol 1992; 39: 11930.
  • 104
    Rao SP, Miller ST, Cohen BJ. Transient aplastic crisis in patients with sickle cell disease. B19 parvovirus studies during a 7-year period. Am J Dis Child 1992; 146: 132830.
  • 105
    Muir K, Todd WT, Watson WH, Fitzsimons E. Viral-associated haemophagocytosis with parvovirus-B19-related pancytopenia. Lancet 1992; 339: 113940.
  • 106
    Rao SP, Desai N, Miller ST. B19 parvovirus infection and transient aplastic crisis in a child with sickle cell anemia. J Pediatr Hematol Oncol 1996; 18: 1757.
  • 107
    Saarinen UM, Chorba TL, Tattersall P et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986; 67: 14117.
  • 108
    Smith-Whitley K, Zhao H, Hodinka RL et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 2004; 103: 4227.
  • 109
    Morey AL, Keeling JW, Porter HJ, Fleming KA. Clinical and histopathological features of parvovirus B19 infection in the human fetus. Br J Obstet Gynaecol 1992; 99: 56674.
  • 110
    Beghetti M, Gervaix A, Haenggeli CA, Berner M, Rimensberger PC. Myocarditis associated with parvovirus B19 infection in two siblings with merosin-deficient congenital muscular dystrophy. Eur J Pediatr 2000; 159: 1356.
  • 111
    Enders G, Dotsch J, Bauer J et al. Life-threatening parvovirus B19-associated myocarditis and cardiac transplantation as possible therapy: two case reports. Clin Infect Dis 1998; 26: 3558.
  • 112
    Saint-Martin J, Choulot JJ, Bonnaud E, Morinet F. Myocarditis caused by parvovirus. J Pediatr 1990; 116: 10078.
  • 113
    Chia JK, Jackson B. Myopericarditis due to parvovirus B19 in an adult. Clin Infect Dis 1996; 23: 2001.
  • 114
    Papadogiannakis N, Tolfvenstam T, Fischler B, Norbeck O, Broliden K. Active, fulminant, lethal myocarditis associated with parvovirus B19 infection in an infant. Clin Infect Dis 2002; 35: 102731.
  • 115
    Gutersohn A, Zimmermann U, Bartel T, Erbel R. A rare case of acute ‘infective’ myocardial infarction triggered by acute parvovirus B19 myocarditis. Nat Clin Pract Cardiovasc Med 2005; 2: 16771.
  • 116
    Langnas AN, Markin RS, Cattral MS, Naides SJ. Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology 1995; 22: 16615.
  • 117
    Sokal EM, Melchior M, Cornu C et al. Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children. Lancet 1998; 352: 173941.
  • 118
    Hillingso JG, Jensen IP, Tom-Petersen L. Parvovirus B19 and acute hepatitis in adults. Lancet 1998; 351: 9556.
  • 119
    Nagai K, Morohoshi T, Kudoh T, Yoto Y, Suzuki N, Matsunaga Y. Transient erythroblastopenia of childhood with megakaryocytopenia associated with human parvovirus B19 infection. Br J Haematol 1992; 80: 1312.
  • 120
    Scheurlen W, Ramasubbu K, Wachowski O, Hemauer A, Modrow S. Chronic autoimmune thrombopenia/neutropenia in a boy with persistent parvovirus B19 infection. J Clin Virol 2001; 20: 1738.
  • 121
    Heegaard ED, Rosthoj S, Petersen BL, Nielsen S, Karup Pedersen F, Hornsleth A. Role of parvovirus B19 infection in childhood idiopathic thrombocytopenic purpura. Acta Paediatr 1999; 88: 6147.
  • 122
    Nigro G, Zerbini M, Krzysztofiak A et al. Active or recent parvovirus B19 infection in children with Kawasaki disease. Lancet 1994; 343: 12601.
  • 123
    Smith SB, Libow LF, Elston DM, Bernert RA, Warschaw KE. Gloves and socks syndrome: early and late histopathologic features. J Am Acad Dermatol 2002; 47: 74954.
  • 124
    Barah F, Vallely PJ, Chiswick ML, Cleator GM, Kerr JR. Association of human parvovirus B19 infection with acute meningoencephalitis. Lancet 2001; 358: 72930.
  • 125
    Kerr JR, Barah F, Chiswick ML et al. Evidence for the role of demyelination, HLA-DR alleles, and cytokines in the pathogenesis of parvovirus B19 meningoencephalitis and its sequelae. J Neurol Neurosurg Psychiatry 2002; 73: 73946.
  • 126
    Jacobson SK, Daly JS, Thorne GM, McIntosh K. Chronic parvovirus B19 infection resulting in chronic fatigue syndrome: case history and review. Clin Infect Dis 1997; 24: 104851.
  • 127
    Kerr JR, Bracewell J, Laing I et al. Chronic fatigue syndrome and arthralgia following parvovirus B19 infection. J Rheumatol 2002; 29: 595602.
  • 128
    Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002; 15: 485505.
  • 129
    Nikkari S, Roivainen A, Hannonen P et al. Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann Rheum Dis 1995; 54: 597600.
  • 130
    Wong S, Young NS, Brown KE. Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associated aplastic anemia. J Infect Dis 2003; 187: 15816.
  • 131
    Vuorinen T, Lammintausta K, Kotilainen P, Nikkari S. Presence of parvovirus B19 DNA in chronic urticaric and healthy human skin. J Clin Virol 2002; 25: 21721.
  • 132
    Koch WC, Massey G, Russell CE, Adler SP. Manifestations and treatment of human parvovirus B19 infection in immunocompromised patients. J Pediatr 1990; 116: 3559.
  • 133
    Weiland HT, Salimans MM, Fibbe WE, Kluin PM, Cohen BJ. Prolonged parvovirus B19 infection with severe anaemia in a bone marrow transplant patient. Br J Haematol 1989; 71: 300.
  • 134
    Frickhofen N, Arnold R, Hertenstein B, Wiesneth M, Young NS. Parvovirus B19 infection and bone marrow transplantation. Ann Hematol 1992; 64(Suppl.): A1214.
  • 135
    Hasle H, Heegaard E, Kerndrup G, Jensen IM, Peterslund NA, Hornsleth A. Parvovirus B19 infection infrequently involved in children and adults with myelodysplastic syndrome. Leuk Res 1996; 20: 813.
  • 136
    Heegaard ED, Myhre J, Hornsleth A, Gundestrup M, Boye H. Parvovirus B19 infections in patients with chronic anemia. Haematologica 1997; 82: 4025.
  • 137
    Frickhofen N, Abkowitz JL, Safford M et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113: 92633.
  • 138
    Azzi A, Fanci R, Ciappi S, Zakrzewska K, Bosi A. Human parvovirus B19 infection in bone marrow transplantation patients. Am J Hematol 1993; 44: 2079.
  • 139
    Nour B, Green M, Michaels M et al. Parvovirus B19 infection in pediatric transplant patients. Transplantation 1993; 56: 8358.
  • 140
    Graeve JL, De Alarcon PA, Naides SJ. Parvovirus B19 infection in patients receiving cancer chemotherapy: the expanding spectrum of disease. Am J Pediatr Hematol Oncol 1989; 11: 4414.
  • 141
    Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese RM, Young NS. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989; 84: 111423.
  • 142
    Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years’ duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321: 51923.
  • 143
    Young NS. Parvovirus infection and its treatment. Clin Exp Immunol 1996; 104(Suppl. 1): 2630.
  • 144
    Chen MY, Hung CC, Fang CT, Hsieh SM. Reconstituted immunity against persistent parvovirus B19 infection in a patient with acquired immunodeficiency syndrome after highly active antiretroviral therapy. Clin Infect Dis 2001; 32: 13615.
  • 145
    Lundqvist A, Tolfvenstam T, Bostic J, Soderlund M, Broliden K. Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow. Scand J Infect Dis 1999; 31: 116.
  • 146
    Matano S, Kinoshita H, Tanigawa K, Terahata S, Sugimoto T. Acute parvovirus B19 infection mimicking chronic fatigue syndrome. Intern Med 2003; 42: 9035.
  • 147
    Kerr JR, Tyrrell DA. Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome. Curr Pain Headache Rep 2003; 7: 33341.
  • 148
    Tolfvenstam T, Lundqvist A, Levi M, Wahren B, Broliden K. Mapping of B-cell epitopes on human parvovirus B19 non-structural and structural proteins. Vaccine 2000; 19: 75863.
  • 149
    Isa A, Norbeck O, Hirbod T et al. Aberrant cellular immune responses in humans infected persistently with parvovirus B19. J Med Virol 2006; 78: 12933.
  • 150
    Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996; 174: 3742.
  • 151
    Yaegashi N, Niinuma T, Chisaka H et al. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J Infect 1998; 37: 2835.
  • 152
    Brown T, Anand A, Ritchie LD, Clewley JP, Reid TM. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 1984; 2: 10334.
  • 153
    Kerr JR, O'Neill HJ, Coyle PV, Thompson W. An outbreak of parvovirus B19 infection; a study of clinical manifestations and the incidence of fetal loss. Ir J Med Sci 1994; 163: 657.
  • 154
    Harger JH, Adler SP, Koch WC, Harger GF. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol 1998; 91: 41320.
  • 155
    Anand A, Gray ES, Brown T, Clewley JP, Cohen BJ. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med 1987; 316: 1836.
  • 156
    Eis-Hubinger AM, Dieck D, Schild R, Hansmann M, Schneweis KE. Parvovirus B19 infection in pregnancy. Intervirology 1998; 41: 17884.
  • 157
    Enders G, Biber M. Parvovirus B19 infections in pregnancy. Behring Inst Mitt 1990; 85: 748.
  • 158
    Rodis JF, Borgida AF, Wilson M et al. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians. Am J Obstet Gynecol 1998; 179: 9858.
  • 159
    Garcia AG, Pegado CS, Cubel Rde C, Fonseca ME, Sloboda I, Nascimento JP. Feto-placentary pathology in human parvovirus B19 infection. Rev Inst Med Trop Sao Paulo 1998; 40: 14550.
  • 160
    Sheikh AU, Ernest JM, O'Shea M. Long-term outcome in fetal hydrops from parvovirus B19 infection. Am J Obstet Gynecol 1992; 167: 33741.
  • 161
    Nunoue T, Kusuhara K, Hara T. Human fetal infection with parvovirus B19: maternal infection time in gestation, viral persistence and fetal prognosis. Pediatr Infect Dis J 2002; 21: 11336.
  • 162
    Nyman M, Skjoldebrand-Sparre L, Broliden K. Non-hydropic intrauterine fetal death more than 5 months after primary parvovirus B19 infection. J Perinat Med 2005; 33: 1768.
  • 163
    Kinney JS, Anderson LJ, Farrar J et al. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J Infect Dis 1988; 157: 6637.
  • 164
    Katz VL, McCoy MC, Kuller JA, Hansen WF. An association between fetal parvovirus B19 infection and fetal anomalies: a report of two cases. Am J Perinatol 1996; 13: 435.
  • 165
    Tiessen RG, Van Elsacker-Niele AM, Vermeij-Keers C, Oepkes D, Van Roosmalen J, Gorsira MC. A fetus with a parvovirus B19 infection and congenital anomalies. Prenat Diagn 1994; 14: 1736.
  • 166
    Weiland HT, Vermey-Keers C, Salimans MM, Fleuren GJ, Verwey RA, Anderson MJ. Parvovirus B19 associated with fetal abnormality. Lancet 1987; 1: 6823.
  • 167
    Guidozzi F, Ballot D, Rothberg AD. Human B19 parvovirus infection in an obstetric population. A prospective study determining fetal outcome. J Reprod Med 1994; 39: 368.
  • 168
    Skjoldebrand-Sparre L, Tolfvenstam T, Papadogiannakis N, Wahren B, Broliden K, Nyman M. Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG 2000; 107: 47680.
  • 169
    Tolfvenstam T, Papadogiannakis N, Norbeck O, Petersson K, Broliden K. Frequency of human parvovirus B19 infection in intrauterine fetal death. Lancet 2001; 357: 14947.
  • 170
    Norbeck O, Papadogiannakis N, Petersson K, Hirbod T, Broliden K, Tolfvenstam T. Revised clinical presentation of parvovirus B19-associated intrauterine fetal death. Clin Infect Dis 2002; 35: 10328.
  • 171
    Nyman M, Tolfvenstam T, Petersson K, Krassny C, Skjoldebrand-Sparre L, Broliden K. Detection of human parvovirus B19 infection in first-trimester fetal loss. Obstet Gynecol 2002; 99: 7958.
  • 172
    Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 2004; 24: 5138.
  • 173
    Jordan JA, Huff D, DeLoia JA. Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin Diagn Lab Immunol 2001; 8: 28892.
  • 174
    Jordan JA, Butchko AR. Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 Cytodeath antibody. Placenta 2002; 23: 54753.
  • 175
    Von Kaisenberg CS, Bender G, Scheewe J et al. A case of fetal parvovirus B19 myocarditis, terminal cardiac heart failure, and perinatal heart transplantation. Fetal Diagn Ther 2001; 16: 42732.
  • 176
    Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 2005; 193: 3635.
  • 177
    Musiani M, Zerbini M, Gentilomi G, Plazzi M, Gallinella G, Venturoli S. Parvovirus B19 clearance from peripheral blood after acute infection. J Infect Dis 1995; 172: 13603.
  • 178
    Cassinotti P, Siegl G. Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur J Clin Microbiol Infect Dis 2000; 19: 8867.
  • 179
    Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997; 53: 22932.
  • 180
    Lindblom A, Isa A, Norbeck O et al. Slow clearance of human parvovirus B19 viremia following acute infection. Clin Infect Dis 2005; 41: 12013.
  • 181
    McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309: 137.
  • 182
    Kagi D, Ledermann B, Burki K et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 317.
  • 183
    Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499512.
  • 184
    Tolfvenstam T, Oxenius A, Price DA et al. Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19. J Virol 2001; 75: 5403.
  • 185
    Franssila R, Hokynar K, Hedman K. T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus B19. J Infect Dis 2001; 183: 8059.
  • 186
    Von Poblotzki A, Gerdes C, Reischl U, Wolf H, Modrow S. Lymphoproliferative responses after infection with human parvovirus B19. J Virol 1996; 70: 732730.
  • 187
    Corcoran A, Doyle S, Waldron D, Nicholson A, Mahon BP. Impaired gamma interferon responses against parvovirus B19 by recently infected children. J Virol 2000; 74: 990310.
  • 188
    Franssila R, Auramo J, Modrow S et al. T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity. Clin Exp Immunol 2005; 142: 5361.
  • 189
    Lindner J, Barabas S, Saar K et al. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection. J Vet Med B Infect Dis Vet Public Health 2005; 52: 35661.
  • 190
    Mitchell LA, Leong R, Rosenke KA. Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy? J Med Microbiol 2001; 50: 62735.
  • 191
    Norbeck O, Isa A, Pohlmann C et al. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 2005; 79: 1211721.
  • 192
    Isa A, Kasprowicz V, Norbeck O et al. Prolonged activation of virus-specific CD8+ T cells after acute B19 infection. PLoS Med 2005; 2: e343.
  • 193
    Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002; 195: 893905.
  • 194
    Saikawa T, Anderson S, Momoeda M, Kajigaya S, Young NS. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol 1993; 67: 30049.
  • 195
    Kerr S, O'Keeffe G, Kilty C, Doyle S. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol 1999; 57: 17985.
  • 196
    Manaresi E, Gallinella G, Zerbini M, Venturoli S, Gentilomi G, Musiani M. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay. J Med Virol 1999; 57: 1748.
  • 197
    Badovinac VP, Porter BB, Harty JT. Programmed contraction of CD8(+) T cells after infection. Nat Immunol 2002; 3: 61926.
  • 198
    Hou S, Hyland L, Ryan KW, Portner A, Doherty PC. Virus-specific CD8+ T-cell memory determined by clonal burst size. Nature 1994; 369: 6524.
  • 199
    Zhou S, Ou R, Huang L, Price GE, Moskophidis D. Differential tissue-specific regulation of antiviral CD8+ T-cell immune responses during chronic viral infection. J Virol 2004; 78: 3578600.
  • 200
    Probst HC, Tschannen K, Gallimore A et al. Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J Immunol 2003; 171: 541522.
  • 201
    Nayersina R, Fowler P, Guilhot S et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993; 150: 465971.
  • 202
    Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97: 165565.
  • 203
    Corcoran A, Crowley B, Dewhurst C, Pizer BL, Doyle S. Establishment of functional B cell memory against parvovirus B19 capsid proteins may be associated with resolution of persistent infection. J Med Virol 2006; 78: 1258.
  • 204
    Shneerson JM, Mortimer PP, Vandervelde EM. Febrile illness due to a parvovirus. Br Med J 1980; 280: 1580.
  • 205
    Erdman DD, Usher MJ, Tsou C et al. Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol 1991; 35: 1105.
  • 206
    Bluth MH, Norowitz KB, Chice S et al. Detection of IgE anti-parvovirus B19 and increased CD23+ B cells in parvovirus B19 infection: relation to Th2 cytokines. Clin Immunol 2003; 108: 1528.
  • 207
    Von Poblotzki A, Hemauer A, Gigler A et al. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Infect Dis 1995; 172: 13569.
  • 208
    Von Poblotzki A, Gigler A, Lang B, Wolf H, Modrow S. Antibodies to parvovirus B19 NS-1 protein in infected individuals. J Gen Virol 1995; 76: 51927.
  • 209
    Hemauer A, Gigler A, Searle K et al. Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women. J Med Virol 2000; 60: 4855.
  • 210
    Jones LP, Erdman DD, Anderson LJ. Prevalence of antibodies to human parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection. J Infect Dis 1999; 180: 5004.
  • 211
    Searle K, Schalasta G, Enders G. Development of antibodies to the nonstructural protein NS1 of parvovirus B19 during acute symptomatic and subclinical infection in pregnancy: implications for pathogenesis doubtful. J Med Virol 1998; 56: 1928.
  • 212
    Venturoli S, Gallinella G, Manaresi E, Gentilomi G, Musiani M, Zerbini M. IgG response to the immunoreactive region of parvovirus B19 nonstructural protein by immunoblot assay with a recombinant antigen. J Infect Dis 1998; 178: 18269.
  • 213
    De Jong EP, De Haan TR, Kroes AC, Beersma MF, Oepkes D, Walther FJ. Parvovirus B19 infection in pregnancy. J Clin Virol 2006; 36: 17.
  • 214
    Enders M, Schalasta G, Baisch C et al. Human parvovirus B19 infection during pregnancy – value of modern molecular and serological diagnostics. J Clin Virol 2006; 35: 4006.
  • 215
    Skjoldebrand-Sparre L, Nyman M, Broliden K, Wahren B. All cases of intrauterine fetal death should be evaluated for parvovirus B19 viral deoxyribonucleic acid. Am J Obstet Gynecol 1999; 180: 15956.
  • 216
    Petersson K, Norbeck O, Westgren M, Broliden K. Detection of parvovirus B19, cytomegalovirus and enterovirus infections in cases of intrauterine fetal death. J Perinat Med 2004; 32: 51621.
  • 217
    Wolff K, Broliden K, Marsk A, Tolfvenstam T, Papadogiannakis N, Westgren M. One stillborn and one severely hydropic twin due to parvovirus B19 infection; successful outcome of the surviving twin. Acta Obstet Gynecol Scand 1999; 78: 82830.
  • 218
    Knoll A, Louwen F, Kochanowski B et al. Parvovirus B19 infection in pregnancy: quantitative viral DNA analysis using a kinetic fluorescence detection system (TaqMan PCR). J Med Virol 2002; 67: 25966.
  • 219
    Hokynar K, Norja P, Laitinen H et al. Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests. J Clin Microbiol 2004; 42: 20139.
  • 220
    Liefeldt L, Plentz A, Klempa B et al. Recurrent high level parvovirus B19/genotype 2 viremia in a renal transplant recipient analyzed by real-time PCR for simultaneous detection of genotypes 1 to 3. J Med Virol 2005; 75: 1619.
  • 221
    Lefrere JJ, Servant-Delmas A, Candotti D et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005; 106: 28905.
  • 222
    Goldstein AR, Anderson MJ, Serjeant GR. Parvovirus associated aplastic crisis in homozygous sickle cell disease. Arch Dis Child 1987; 62: 5858.
  • 223
    Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin – a report of eight patients. Am J Hematol 1999; 61: 1620.
  • 224
    Carstensen H, Ornvold K, Cohen BJ. Human parvovirus B19 infection associated with prolonged erythroblastopenia in a leukemic child. Pediatr Infect Dis J 1989; 8: 56.
  • 225
    Smith MA, Shah NR, Lobel JS, Cera PJ, Gary GW, Anderson LJ. Severe anemia caused by human parvovirus in a leukemia patient on maintenance chemotherapy. Clin Pediatr (Phila) 1988; 27: 3836.
  • 226
    Brennand JE, Cameron AD. Human parvovirus B19 in pregnancy. Hosp Med 2000; 61: 936.
  • 227
    Von Kaisenberg CS, Jonat W. Fetal parvovirus B19 infection. Ultrasound Obstet Gynecol 2001; 18: 2808.
  • 228
    Schild RL, Bald R, Plath H, Eis-Hubinger AM, Enders G, Hansmann M. Intrauterine management of fetal parvovirus B19 infection. Ultrasound Obstet Gynecol 1999; 13: 1616.
  • 229
    Smoleniec JS, Pillai M. Management of fetal hydrops associated with parvovirus B19 infection. Br J Obstet Gynaecol 1994; 101: 107981.
  • 230
    Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998; 105: 1748.
  • 231
    Forestier F, Tissot JD, Vial Y, Daffos F, Hohlfeld P. Haematological parameters of parvovirus B19 infection in 13 fetuses with hydrops foetalis. Br J Haematol 1999; 104: 9257.
  • 232
    Selbing A, Josefsson A, Dahle LO, Lindgren R. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet 1995; 345: 6601.
  • 233
    Matsuda H, Sakaguchi K, Shibasaki T, Takahashi H, Kawakami Y, Furuya K. Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med 2005; 33: 5613.
  • 234
    Ballou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003; 187: 6758.
  • 235
    Bansal GP, Hatfield JA, Dunn FE et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 1993; 167: 103444.
  • 236
    Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350: 58697.
  • 237
    Hung CC, Lee KL, Chen MY. Increase in B19 viral load prior to relapse of anaemia in an AIDS patient with persistent B19 infection. J Infect 2001; 43: 1502.
  • 238
    Pallier C, Greco A, Le Junter J, Saib A, Vassias I, Morinet F. The 3′ untranslated region of the B19 parvovirus capsid protein mRNAs inhibits its own mRNA translation in nonpermissive cells. J Virol 1997; 71: 94829.
  • 239
    Anderson LJ, Young NS (eds). Human Parvovirus B.19, Vol. 20. Basel: Karger, 1997.